MARKET

MITO

MITO

Stealth BioTherapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.480
+0.060
+4.23%
Closed 16:00 10/20 EDT
OPEN
1.420
PREV CLOSE
1.420
HIGH
1.580
LOW
1.410
VOLUME
131.38K
TURNOVER
--
52 WEEK HIGH
14.41
52 WEEK LOW
0.9002
MARKET CAP
73.68M
P/E (TTM)
-1.3999
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Stealth BioTherapeutics Announces Poster Presentation Of Elamipretide For Barth Syndrome At American Society Of Human Genetics (ASHG) Virtual Annual Meeting
BOSTON, Oct. 19, 2020 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for
Benzinga · 1d ago
Stealth BioTherapeutics Announces Poster Presentation at 2020 Annual NEALS Meeting
Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company will present an abstract in a poster session at the upcoming
PR Newswire · 09/23 21:30
Stealth BioTherapeutics (MITO) Investor Presentation - Slideshow
The following slide deck was published by Stealth BioTherapeutics Corp in conjunction with this event.
Seekingalpha · 09/17 18:36
Stealth BioTherapeutics to Present at Upcoming Investor Conferences in September
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the following upcoming virtual
PR Newswire · 09/10 21:30
Stealth BioTherapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the second
PR Newswire · 08/06 11:30
Stealth BioTherapeutics to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report second quar
PR Newswire · 07/30 12:30
Stealth Biotherapeutics Files For Resale Of Up To 9.8M ADSs Of Co By Selling Shareholder
-Reuters
Reuters · 06/22 20:51
Stealth BioTherapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
PR Newswire · 06/17 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MITO. Analyze the recent business situations of Stealth BioTherapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MITO stock price target is 3.950 with a high estimate of 7.00 and a low estimate of 1.750.
EPS
Institutional Holdings
Institutions: 15
Institutional Holdings: 1.05M
% Owned: 2.11%
Shares Outstanding: 49.79M
TypeInstitutionsShares
Increased
2
142.36K
New
3
-8.48K
Decreased
3
60.15K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MITO
Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. The Company is primarily focused on developing mitochondrial targeted therapies for diseases with clear unmet medical needs including cardiovascular, renal, neurodegenerative and metabolic diseases. The Company is engaged in developing its product pipelines, which include Elamipretide, SBT-20 and SBT-272.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Stealth BioTherapeutics Corp stock information, including NASDAQ:MITO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MITO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MITO stock methods without spending real money on the virtual paper trading platform.